# Official Journal C 166/25 J

| | ISSN 1725-2423 |
| --- | --- |
| Official Journal
  of the European Union | C 166 |
| | |
| English edition | Information and Notices | Volume 4725 June 2004 |

ISSN 1725-2423

Official Journal

of the European Union

C 166

English edition

Information and Notices

Volume 4725 June 2004

---

| Notice No | Contents | page |
| --- | --- | --- |
| | I   Information |
| | Commission |
| 2004/C 166/1 | Euro exchange rates | 1 |
| 2004/C 166/2 | Summary of Community decisions on marketing authorizations in respect of medicinal products from 15/05/2004 to 15/06/2004(Published pursuant to Article 12 or Article 34 of Council Regulation (EEC) No 2309/93) | 2 |
| 2004/C 166/3 | Prior notification of a concentration (Case No COMP/M.3505 — TCL / ALCATEL) [Candidate case for simplified procedure] (
  1
  ) | 5 |
| 2004/C 166/4 | Non-opposition to a notified concentration (Case No COMP/M.3391 — XCHANGING/DEUTSCHE BANK/ETB JV) (
  1
  ) | 6 |

Notice No

Contents

page

I   Information

Commission

2004/C 166/1

Euro exchange rates

1

2004/C 166/2

Summary of Community decisions on marketing authorizations in respect of medicinal products from 15/05/2004 to 15/06/2004(Published pursuant to Article 12 or Article 34 of Council Regulation (EEC) No 2309/93)

(Published pursuant to Article 12 or Article 34 of Council Regulation (EEC) No 2309/93)

2

2004/C 166/3

Prior notification of a concentration (Case No COMP/M.3505 — TCL / ALCATEL) [Candidate case for simplified procedure] (
  1
  )

1

5

2004/C 166/4

Non-opposition to a notified concentration (Case No COMP/M.3391 — XCHANGING/DEUTSCHE BANK/ETB JV) (
  1
  )

1

6

| | |
| --- | --- |
| | (1)   Text with EEA relevance |

---

(1)   Text with EEA relevance

1

| EN | |
| --- | --- |

EN

---

I Information

Commission

| 25.6.2004 | EN | Official Journal of the European Union | C 166/1 |
| --- | --- | --- | --- |

25.6.2004

EN

Official Journal of the European Union

C 166/1

---

Euro exchange rates (1)

24 June 2004

(2004/C 166/01)

1 euro=

| | Currency | Exchange rate |
| --- | --- | --- |
| USD | US dollar | 1,2122 |
| JPY | Japanese yen | 130,32 |
| DKK | Danish krone | 7,4324 |
| GBP | Pound sterling | 0,66810 |
| SEK | Swedish krona | 9,1688 |
| CHF | Swiss franc | 1,5130 |
| ISK | Iceland króna | 88,02 |
| NOK | Norwegian krone | 8,3580 |
| BGN | Bulgarian lev | 1,9559 |
| CYP | Cyprus pound | 0,58150 |
| CZK | Czech koruna | 31,613 |
| EEK | Estonian kroon | 15,6466 |
| HUF | Hungarian forint | 253,25 |
| LTL | Lithuanian litas | 3,4528 |
| LVL | Latvian lats | 0,6547 |
| MTL | Maltese lira | 0,4259 |
| PLN | Polish zloty | 4,5582 |
| ROL | Romanian leu | 40 852 |
| SIT | Slovenian tolar | 239,6400 |
| SKK | Slovak koruna | 39,938 |
| TRL | Turkish lira | 1 802 919 |
| AUD | Australian dollar | 1,7412 |
| CAD | Canadian dollar | 1,6330 |
| HKD | Hong Kong dollar | 9,4526 |
| NZD | New Zealand dollar | 1,9228 |
| SGD | Singapore dollar | 2,0746 |
| KRW | South Korean won | 1 400,88 |
| ZAR | South African rand | 7,6491 |

Currency

Exchange rate

USD

US dollar

1,2122

JPY

Japanese yen

130,32

DKK

Danish krone

7,4324

GBP

Pound sterling

0,66810

SEK

Swedish krona

9,1688

CHF

Swiss franc

1,5130

ISK

Iceland króna

88,02

NOK

Norwegian krone

8,3580

BGN

Bulgarian lev

1,9559

CYP

Cyprus pound

0,58150

CZK

Czech koruna

31,613

EEK

Estonian kroon

15,6466

HUF

Hungarian forint

253,25

LTL

Lithuanian litas

3,4528

LVL

Latvian lats

0,6547

MTL

Maltese lira

0,4259

PLN

Polish zloty

4,5582

ROL

Romanian leu

40 852

SIT

Slovenian tolar

239,6400

SKK

Slovak koruna

39,938

TRL

Turkish lira

1 802 919

AUD

Australian dollar

1,7412

CAD

Canadian dollar

1,6330

HKD

Hong Kong dollar

9,4526

NZD

New Zealand dollar

1,9228

SGD

Singapore dollar

2,0746

KRW

South Korean won

1 400,88

ZAR

South African rand

7,6491

---

(1)

Source: reference exchange rate published by the ECB.

---

| 25.6.2004 | EN | Official Journal of the European Union | C 166/2 |
| --- | --- | --- | --- |

25.6.2004

EN

Official Journal of the European Union

C 166/2

---

Summary of Community decisions on marketing authorizations in respect of medicinal products from 15/05/2004 to 15/06/2004

(Published pursuant to Article 12 or Article 34 of Council Regulation (EEC) No 2309/93)

(2004/C 166/02)

Issuing of a marketing authorization (Article 12 of Council Regulation (EEC) No 2309/93) Accepted

| Date of the decision | Name of the medicinal product | Holder of the marketing authorization | Number of the entry in the Community Register | Date of notification |
| --- | --- | --- | --- | --- |
| 01.06.2004 | Levemir | Novo Nordisk A/S, |
| Novo Allé, |
| DK-2880 Bagsvaerd, |

Date of the decision

Name of the medicinal product

Holder of the marketing authorization

Number of the entry in the Community Register

Date of notification

01.06.2004

Levemir

Novo Nordisk A/S,

Novo Allé,

DK-2880 Bagsvaerd,

EU/01/04/278/001-009

04.06.2004

04.06.2004

Abilifly

| Otsuka Pharmaceutical Europe Ltd, |
| --- |
| Common-wealth House, |
| 2 Chalkhill Road, |
| Hammersmith, |
| London W6 8DW, |
| United Kingdom |

Otsuka Pharmaceutical Europe Ltd,

Common-wealth House,

2 Chalkhill Road,

Hammersmith,

London W6 8DW,

United Kingdom

EU/1/04/276/001-020

08.06.2004

08.06.2004

TachoSil

| Nycomed Austria GMBH, |
| --- |
| St.-Peter-Strasse 25, |
| A-4020 Linz, |

Nycomed Austria GMBH,

St.-Peter-Strasse 25,

A-4020 Linz,

EU/1/04/277/001-004

11.06.2004

15.06.2004

Oxybutynin

| Nicobrand Limited, |
| --- |
| 189 Casteroe Road, |
| Coleraine, |
| Northerne Ireland |

Nicobrand Limited,

189 Casteroe Road,

Coleraine,

Northerne Ireland

EU/1/03/270/001-002

18.06.2004

Modification of a marketing authorization (Article 12 of Council Regulation (EEC) No 2309/93) Accepted

| Date of the decision | Name of the medicinal product | Holder of the marketing authorization | Number of the entry in the Community Register | Date of notification |
| --- | --- | --- | --- | --- |
| 19.05.2004 | Protopic | Fujisawa GmbH, |
| Neumarkter Str. 61, |
| D-81673 München, |

Date of the decision

Name of the medicinal product

Holder of the marketing authorization

Number of the entry in the Community Register

Date of notification

19.05.2004

Protopic

Fujisawa GmbH,

Neumarkter Str. 61,

D-81673 München,

EU/1/02/201/001-006

25.05.2004

25.05.2004

Hepsera

| Gilead Sciences International Limited, |
| --- |
| Cambridge CB1 6GT |
| United Kingdom |

Gilead Sciences International Limited,

Cambridge CB1 6GT

United Kingdom

EU/1/03/251/001

27.05.2004

26.05.2004

Viagra

| Pfizer Limited, |
| --- |
| Sandwich, |
| Kent CT13 9NJ, |
| United Kingdom |

Pfizer Limited,

Sandwich,

Kent CT13 9NJ,

United Kingdom

EU/1/98/077/001-012

01.06.2004

26.05.2004

Combivir

| Glaxo Group Ltd., |
| --- |
| Greenford Road, |
| Greenford, |
| Middlesex UB6 0NN |
| United Kingdom |

Glaxo Group Ltd.,

Greenford Road,

Greenford,

Middlesex UB6 0NN

United Kingdom

EU/1/98/058/001-002

01.06.2004

26.05.2004

Ziagen

| Glaxo Group Ltd, |
| --- |
| Greenford, |
| Middlesex UB6 0NN, |
| United Kingdom |

Glaxo Group Ltd,

Greenford,

Middlesex UB6 0NN,

United Kingdom

EU/1/99/112/001-002

01.06.2004

26.05.2004

Taxotere

| Aventis Pharma S.A., |
| --- |
| 20 avenue Raymond Aron, |
| 92165 Antony Cedex, France |

Aventis Pharma S.A.,

20 avenue Raymond Aron,

92165 Antony Cedex, France

EU/1/95/002/001-002

01.06.2004

26.05.2004

TRIZIVIR

| Glaxo Group Ltd, |
| --- |
| Greenford, |
| Middlesex UB6 0NN, |
| United Kingdom |

Glaxo Group Ltd,

Greenford,

Middlesex UB6 0NN,

United Kingdom

EU/1/00/156/001-003

01.06.2004

01.06.2004

Vivanza

| Bayer AG, |
| --- |
| D-51368 Leverkusen, |

Bayer AG,

D-51368 Leverkusen,

EU/1/03/249/001-012

07.06.2004

01.06.2004

Levitra

| Bayer AG, |
| --- |
| D-51368 Leverkusen, |

Bayer AG,

D-51368 Leverkusen,

EU/1/03/248/001-012

07.06.2004

01.06.2004

Epivir

| Glaxo Group Ltd., |
| --- |
| Greenford Road, |
| Greenford, |
| Middlesex UB6 0NN, |
| United Kingdom |

Glaxo Group Ltd.,

Greenford Road,

Greenford,

Middlesex UB6 0NN,

United Kingdom

EU/1/96/015/001-005

07.06.2004

08.06.2004

Remicade

| Centocor B.V., |
| --- |
| Einsteinweg 101, |
| 2333 CB Leiden, |
| Nederland |

Centocor B.V.,

Einsteinweg 101,

2333 CB Leiden,

Nederland

EU/1/99/116/001-003

10.06.2004

08.06.2004

Remicade

| Centocor B.V., |
| --- |
| Einsteinweg 101, |
| 2333 CB Leiden, |
| Nederland |

Centocor B.V.,

Einsteinweg 101,

2333 CB Leiden,

Nederland

EU/1/99/116/001-003

10.06.2004

08.06.2004

Fuzeon

| Roche Registration Limited, |
| --- |
| 40 Broadwater Road, |
| Welwyn Garden City, |
| Hertfordshire AL7 3AY, |
| United Kingdom |

Roche Registration Limited,

40 Broadwater Road,

Welwyn Garden City,

Hertfordshire AL7 3AY,

United Kingdom

EU/1/03/252/001-003

10.06.2004

08.06.2004

Arava

| Aventis Pharma Deutschland GmbH, |
| --- |
| D-65926 Frankfurt am Main, |

Aventis Pharma Deutschland GmbH,

D-65926 Frankfurt am Main,

EU/1/99/118/001-010/

18.06.2004

08.06.2004

Vfend

| Pfizer Limited, |
| --- |
| Sandwich, |
| Kent CT13 9NJ, |
| United Kingdom |

Pfizer Limited,

Sandwich,

Kent CT13 9NJ,

United Kingdom

EU/1/02/212/001-026

10.06.2004

09.06.2004

Vfend

| Pfizer Limited, |
| --- |
| Sandwich, |
| Kent CT13 9NJ, |
| United Kingdom |

Pfizer Limited,

Sandwich,

Kent CT13 9NJ,

United Kingdom

EU/1/02/212/001-026

11.06.2004

10.06.2004

Arava

| Aventis Pharma Deutschland GmbH, |
| --- |
| D-65926 Frankfurt am Main, |

Aventis Pharma Deutschland GmbH,

D-65926 Frankfurt am Main,

EU/1/99/118/001-010/

16.06.2004

10.06.2004

Viread

| Gilead Sciences International Limited, |
| --- |
| Cambridge CB1 6GT |
| United Kingdom |

Gilead Sciences International Limited,

Cambridge CB1 6GT

United Kingdom

EU/1/01/200/001

14.06.2004

10.06.2004

Viread

| Gilead Sciences International Limited, |
| --- |
| Cambridge CB1 6GT |
| United Kingdom |

Gilead Sciences International Limited,

Cambridge CB1 6GT

United Kingdom

EU/1/01/200/001

15.06.2004

10.06.2004

Herceptin

| Roche Registration Limited, |
| --- |
| 40 Broadwater Road, |
| Welwyn Garden City, |
| Hertfordshire AL7 3AY, |
| United Kingdom |

Roche Registration Limited,

40 Broadwater Road,

Welwyn Garden City,

Hertfordshire AL7 3AY,

United Kingdom

EU/1/00/145/001

14.06.2004

10.06.2004

Humira

| Abbott Laboratories Ltd., |
| --- |
| Queenborough, |
| Kent ME11 5EL, |
| United Kingdom |

Abbott Laboratories Ltd.,

Queenborough,

Kent ME11 5EL,

United Kingdom

EU/1/03/256/001-006

14.06.2004

10.06.2004

Trudexa

| Abbott Laboratories Ltd., |
| --- |
| Queenborough, |
| Kent ME11 5EL, |
| United Kingdom |

Abbott Laboratories Ltd.,

Queenborough,

Kent ME11 5EL,

United Kingdom

EU/1/03/257/001-006

14.06.2004

15.06.2004

Xigris

| Eli Lilly Nederland B.V., |
| --- |
| Grootslag 1-5, |
| 3991 RA Houten, |
| Nederland |

Eli Lilly Nederland B.V.,

Grootslag 1-5,

3991 RA Houten,

Nederland

EU/1/02/225/001-002

17.06.2004

---

| 25.6.2004 | EN | Official Journal of the European Union | C 166/5 |
| --- | --- | --- | --- |

25.6.2004

EN

Official Journal of the European Union

C 166/5

---

Prior notification of a concentration

(Case No COMP/M.3505 — TCL / ALCATEL)

[Candidate case for simplified procedure]

(2004/C 166/03)

(Text with EEA relevance)

| 1. | On 17/06/2004, the Commission received a notification of a proposed concentration pursuant to Article 4 of Council Regulation (EC) No 139/2004 (1) by which TCL Communication Technology Holding Ltd (‘TCL’ China), acquires within the meaning of Article 3(1)(b) of the Council Regulation control of the whole of Alcatel Mobile Phone Division (‘AMPD’, France) by way of purchase of shares. |
| --- | --- |

1.

On 17/06/2004, the Commission received a notification of a proposed concentration pursuant to Article 4 of Council Regulation (EC) No 139/2004 (1) by which TCL Communication Technology Holding Ltd (‘TCL’ China), acquires within the meaning of Article 3(1)(b) of the Council Regulation control of the whole of Alcatel Mobile Phone Division (‘AMPD’, France) by way of purchase of shares.

| 2. | The business activities of the undertakings concerned are:






  — | TCL: manufacture and distribution of mobile handsets |
| --- | --- | --- |

2.

The business activities of the undertakings concerned are:

—

TCL: manufacture and distribution of mobile handsets

| — | AMPD: design and distribution of mobile handsets |
| --- | --- |

—

AMPD: design and distribution of mobile handsets

| 3. | On preliminary examination, the Commission finds that the notified concentration could fall within the scope of Regulation (EC) No 139/2004. However, the final decision on this point is reserved. Pursuant to the Commission Notice on a simplified procedure for treatment of certain concentrations under Council Regulation (EEC) No 4064/89 (2) it should be noted that this case is a candidate for treatment under the procedure set out in the Notice. |
| --- | --- |

3.

On preliminary examination, the Commission finds that the notified concentration could fall within the scope of Regulation (EC) No 139/2004. However, the final decision on this point is reserved. Pursuant to the Commission Notice on a simplified procedure for treatment of certain concentrations under Council Regulation (EEC) No 4064/89 (2) it should be noted that this case is a candidate for treatment under the procedure set out in the Notice.

| 4. | The Commission invites interested third parties to submit their possible observations on the proposed operation to the Commission.
  Observations must reach the Commission not later than 10 days following the date of this publication. Observations can be sent to the Commission by fax (fax no. +32/2/2964301 or 2967244) or by post, under reference number COMP/M.3505 - TCL / ALCATEL, to the following address:





  European Commission |
| --- | --- |
| Directorate-General for Competition, |
| Merger Registry |
| J-70 |
| B-1049 Bruxelles/Brussel |

4.

The Commission invites interested third parties to submit their possible observations on the proposed operation to the Commission.

Observations must reach the Commission not later than 10 days following the date of this publication. Observations can be sent to the Commission by fax (fax no. +32/2/2964301 or 2967244) or by post, under reference number COMP/M.3505 - TCL / ALCATEL, to the following address:

European Commission

Directorate-General for Competition,

Merger Registry

J-70

B-1049 Bruxelles/Brussel

---

(1)  OJ L 24, 29.1.2004 p. 1.

(2)  OJ C 217, 29.7.2000, p. 32; Council Regulation (EEC) No 4064/89 has been replaced by Council Regulation (EC) No 139/2004.

---

| 25.6.2004 | EN | Official Journal of the European Union | C 166/6 |
| --- | --- | --- | --- |

25.6.2004

EN

Official Journal of the European Union

C 166/6

---

Non-opposition to a notified concentration

(Case No COMP/M.3391 — XCHANGING/DEUTSCHE BANK/ETB JV)

(2004/C 166/04)

(Text with EEA relevance)

On 28/04/2004, the Commission decided not to oppose the above notified concentration and to declare it compatible with the common market. This decision is based on Article 6(1)(b) of Council Regulation (EEC) No 4064/89. The full text of the decision is available only in English and will be made public after it is cleared of any business secrets it may contain. It will be available:

| — | from the Europa competition web site (http://europa.eu.int/comm/competition/mergers/cases/ ) free of charge. This web site provides various facilities to help locate individual merger decisions, including company, case number, date and sectoral indexes. |
| --- | --- |

—

from the Europa competition web site (http://europa.eu.int/comm/competition/mergers/cases/ ) free of charge. This web site provides various facilities to help locate individual merger decisions, including company, case number, date and sectoral indexes.

| — | in electronic form in the ‘CEN’ version of the CELEX database, under document number 304M3391. CELEX is the computerized documentation system of European Community law. For more information on how to access Celex, see ‘subscriber information’ links below:
  CELEX: subscriber information
  http://publications.eu.int/general/en/eulaw_en.htm |
| --- | --- |

—

in electronic form in the ‘CEN’ version of the CELEX database, under document number 304M3391. CELEX is the computerized documentation system of European Community law. For more information on how to access Celex, see ‘subscriber information’ links below:

CELEX: subscriber information

http://publications.eu.int/general/en/eulaw_en.htm

---